Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2018 · 10-Q
Revenue$40.41M$40.41M+256.2% vs Q2 2017 Net Income-$68.75M-$68.75MN/M vs Q2 2017 EPS Diluted-$1.19-$1.19N/M vs Q2 2017 Operating Income-$72,949,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$68,756,000N/M Margins · derivedOperating margin-180.5%+565.1 pt vs Q2 2017
Net margin-170.1%+562.2 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 2, 2018 · 33 d after period end